Osteoporosis - secondary prevention (replaced by TA161)
The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women
Summary
This guidance has been replaced by TA161 Osteoporosis - secondary prevention including strontium ranelate. NICE has made the following recommendations about the use of bisphosphonates, raloxifene and teriparatide. The recommendations concern the use of these medicines to reduce the risk of furthe ...
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA87
Issued: January 2005
How this guidance was produced